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Long-term Follow-up of HCV Infected Patients; Updated
Results of the EBMT Prospective Study
Per Ljungman, Anna Locasciulli, Albert Békássy, Lorentz Brinch,
Ildefonso Espigado, Augustin Ferrant, Ian Franklin, Valle
Gomez-Garcia de Soria, Joan O' Riordan, Montserrat Rovira,
Peter Shaw, Herman Einsele. On behalf of the Infectious Diseases
Working Party of the EBMT
Introduction: Many long-term survivors after stem cell transplan-
tation (SCT) are infected with HCV. It has been reported that a high
proportion of these patients develop late occurring liver cirrhosis.
Treatment options include interferon with or without the addition
of ribavirin but the knowledge about these options' effectiveness is
limited. Therefore in 1992, the Infectious Diseases Working Party of
the European Group for Blood and Marrow Transplantation (EBMT)
initiated a prospective study of HCV infected SCT patients having
survived at least 6 months after SCT. The intention is to every five
years ask for follow-up on living patients. Two hundred and forty-
seven patients were included in the study cohort between 1992 and
1997.
Report: This is the 3rd report of this cohort. Due to limited follow-
up data, 49 patients have been excluded. Thus, the report is based
on 198 patients with a median follow-up of 16 years (0.52–32.8).
The Kaplan-Meier estimate of survival is 73.9%. Forty patients have
died of whom 8 have been reported to have died from liver asso-
ciated complications including two after liver transplantation. One
additional patient is alive after liver transplantation. Eighty-two
patients have been treated with interferon with or without the ad-
dition of ribavirin or with ribavirin alone. Thirty-six of eighty-two
patients became HCV PCR negative of whom 4 have relapsed with
positive HCV PCR. The side effect profile was similar to other pa-
tient populations treated for HCV.
Conclusion: In this prospectively followed cohort, the prognosis of
chronic HCV infection was quite favourable. Treatment is feasible
and associated with acceptable efficacy and toxicity.
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Single Center over 20 years
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Jong-Wook Lee, Woo-Sung Min, Wan-Shick Shin, Chun-Choo Kim.
The Catholic Hematopoietic Stem Cell Transplantation Center,
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Background: The pattern of infections in hematopoietic stem cell
transplantation (HSCT) recipients has been changing by the diver-
gence in recipient-donor relationships, the intensity of the condi-
tioning regimens, prophylaxis and treatment for graft-versus-host
disease, prophylaxis and preemptive therapy with antimicrobial
agents, and new diagnostic tools.
Objectives: To analyze the changes in infectious complications re-
lated to HSCT in a single center over two decades.
Methods: We conducted a retrospective review of medical records
for all patients who underwent HSCT in the Catholic HSCT center
from 1983 to 2005.
Results: The incidence of neutropenic fever has remained in the
range of 50%-64% and has not changed significantly during the
last 20 years. The incidences of microbiologically documented in-
fections and clinically documented infections have increased but
the incidence of unexplained fever has decreased. Contrary to
the predominance of Gram-positive bacteria in the Western world,
the prevalence of Gram-negative bacteria was higher throughout
the whole period. P. aeruginosa was the most frequently isolated
Gram-negative bacteria until the mid 1990s, and was replaced
by E.coli since the introduction of quinolone prophylaxis for neu-
tropenia. Also since 1997, Streptococcus spp. and Enterococcus
spp. emerged more frequently. Until the mid 1990s, the incidence
of respiratory tract infections was highest, but was replaced by
gastrointestinal infections including oropharyngeal mucositis since
the late 1990s. During pre-engraftment period, overall mortality
has not changed significantly during last 20 years, but infection-
related mortality has gradually decreased, up to 0% in the last
year.
Conclusions: This report on infective complications related HSCT
in the Catholic HSCT Center during the last 20 years will be helpful
in predicting and preventing future infections and making treat-
ment strategies in parallel to the advance and changes in the meth-
ods of HSCT.
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Safety and Immunogenicity of Adult Formulation Tetanus
and Diphtheria Toxoids Adsorbed Combined with Acellular
Pertussis Vaccine Following Blood and Marrow
Transplantation in Adults
Shelly McNeil, Monique MacFarlane-Conrad, Stephen Couban,
Jo-Anne Edwards, Scott Halperin. Canadian Centre for
Vaccinology, IWK Health Centre and Department of Medicine
Dalhousie University Halifax, Nova Scotia, Canada
Background: Blood and Marrow Transplantation (BMT) has become
standard therapy for many disorders. After BMT, recipients are sus-
ceptible to vaccine-preventable infection; protection is achieved
by re-immunizing with a primary vaccine series. While booster im-
munization against pertussis (Tdap) is now recommended for all
adults, evaluation of the safety and immunogenicity of Tdap fol-
lowing BMT is needed to establish optimal number and timing of
doses to ensure protection.
Methods: In this pilot study, patients 18-64 years of age within
1 year post-allogeneic or autologous BMT who were due for post-
transplant vaccines were enrolled. Patients with severe GVHD, ac-
tive infection, or disease relapse were excluded. Patients received
all routine immunizations plus Tdap at 12, 14, 20 months post-BMT.
Serum IgG titres to pertussis (FHA, FIM, PT, PRN), tetanus and diph-
theria antigens were determined by ELISA at baseline and before
and 8 weeks after each dose.
Results: Twelve patients (3 auto, 9 allo) were enrolled; data on
completed participants is presented. No injection site or systemic
adverse reactions were observed after dose 1; after doses 2 and
3, mild arm tenderness was the most common adverse event re-
ported (50%). At baseline, no patient had detectable IgG to per-
tussis antigens. Response to the pertussis component of Tdap was
very poor with post-immunization titres, even following dose 3,
far below those achieved by healthy adults; seroconversion was
observed only to FIM and PRN; no participant responded to PT (see
table). All participants developed protective responses to tetanus
and diphtheria toxoids.
Table 1. Geometric Mean Antibody titres (EU/ml) at baseline and 8 weeks
following the third dose of Tdap
Subject PT FHA FIM PRN
1 12 11 207 11
2 7 7 93 34
3 10 14 108 17
4 17 37 320 51
5 10 31 74 80
6 17 13 176
Discussion: Tdap is well-tolerated as a 3-dose regime following
